Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.00.

Several research firms have recently weighed in on ENTA. JMP Securities increased their price objective on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a "market outperform" rating in a report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Wall Street Zen raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ENTA. Tower Research Capital LLC TRC boosted its stake in shares of Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after buying an additional 2,274 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Enanta Pharmaceuticals by 8.2% in the first quarter. American Century Companies Inc. now owns 40,004 shares of the biotechnology company's stock valued at $221,000 after purchasing an additional 3,042 shares during the period. AlphaQuest LLC boosted its holdings in Enanta Pharmaceuticals by 16.4% during the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after buying an additional 3,137 shares in the last quarter. Invesco Ltd. boosted its holdings in Enanta Pharmaceuticals by 7.3% during the fourth quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company's stock worth $268,000 after buying an additional 3,186 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth about $26,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Price Performance

Shares of ENTA traded up $0.10 during midday trading on Tuesday, reaching $7.21. 99,174 shares of the stock were exchanged, compared to its average volume of 285,443. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.24. The company has a market capitalization of $154.13 million, a price-to-earnings ratio of -1.46 and a beta of 0.81. The business's 50-day moving average price is $5.45 and its 200 day moving average price is $6.23.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). The firm had revenue of $14.93 million for the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, equities research analysts expect that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.